Cargando…

Estrogen Receptor Antagonists Are Anti-Cryptococcal Agents That Directly Bind EF Hand Proteins and Synergize with Fluconazole In Vivo

Cryptococcosis is an infectious disease of global significance for which new therapies are needed. Repurposing previously developed drugs for new indications can expedite the translation of new therapies from bench to beside. Here, we characterized the anti-cryptococcal activity and antifungal mecha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butts, Arielle, Koselny, Kristy, Chabrier-Roselló, Yeissa, Semighini, Camile P., Brown, Jessica C. S., Wang, Xuying, Annadurai, Sivakumar, DiDone, Louis, Tabroff, Julie, Childers, Wayne E., Abou-Gharbia, Magid, Wellington, Melanie, Cardenas, Maria E., Madhani, Hiten D., Heitman, Joseph, Krysan, Damian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Microbiology 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950514/ https://www.ncbi.nlm.nih.gov/pubmed/24520056 http://dx.doi.org/10.1128/mBio.00765-13

Ejemplares similares

Deletion of Cryptococcus neoformans AIF Ortholog Promotes Chromosome Aneuploidy and Fluconazole-Resistance in a Metacaspase-Independent Manner
por: Semighini, Camile P., et al.
Publicado: (2011)

Structure-Activity Relationships for the Antifungal Activity of Selective Estrogen Receptor Antagonists Related to Tamoxifen
por: Butts, Arielle, et al.
Publicado: (2015)

Antitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase
por: Koselny, Kristy, et al.
Publicado: (2016)

Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
por: Mpoza, Edward, et al.
Publicado: (2017)

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2019)

An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2021)

Antifungal Drug Discovery: Something Old and Something New
por: Butts, Arielle, et al.
Publicado: (2012)

A Large-Scale Complex Haploinsufficiency-Based Genetic Interaction Screen in Candida albicans: Analysis of the RAM Network during Morphogenesis
por: Bharucha, Nike, et al.
Publicado: (2011)

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
por: Zhao, Hua-Zhen, et al.
Publicado: (2018)

Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
por: Stone, Neil R.H., et al.
Publicado: (2019)

Candida albicans Morphogenesis Is Not Required for Macrophage Interleukin 1β Production
por: Wellington, Melanie, et al.
Publicado: (2012)

Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients
por: Nasri, Hashem, et al.
Publicado: (2016)

88462 Fluconazole distribution in CNS and gynecological tissues in HIV-related cryptococcal meningitis decedents
por: Nicol, Melanie R., et al.
Publicado: (2021)

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance
por: Hope, William, et al.
Publicado: (2019)

Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
por: Shiri, Tinevimbo, et al.
Publicado: (2020)

Quorum Sensing in Fungi: Q&A
por: Madhani, Hiten D.
Publicado: (2011)

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
por: Schaars, CF, et al.
Publicado: (2006)

Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis
por: Molloy, Síle F., et al.
Publicado: (2018)

A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis
por: Forbes, Lauren, et al.
Publicado: (2015)

Induction therapy with high‐dose fluconazole plus flucytosine for human immunodeficiency virus‐uninfected cryptococcal meningitis patients: Feasible or not?
por: Zhao, Hua‐Zhen, et al.
Publicado: (2022)

High-Throughput Screen in Cryptococcus neoformans Identifies a Novel Molecular Scaffold That Inhibits Cell Wall Integrity Pathway Signaling
por: Hartland, Kate, et al.
Publicado: (2015)

A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi
por: Gaskell, Katherine M., et al.
Publicado: (2014)

1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China
por: Lu, Yanqiu, et al.
Publicado: (2023)

A Genome-Wide Screen of Deletion Mutants in the Filamentous Saccharomyces cerevisiae Background Identifies Ergosterol as a Direct Trigger of Macrophage Pyroptosis
por: Koselny, Kristy, et al.
Publicado: (2018)

Nonredundant Requirement for Multiple Histone Modifications for the Early Anaphase Release of the Mitotic Exit Regulator Cdc14 from Nucleolar Chromatin
por: Hwang, William W., et al.
Publicado: (2009)

Ctr2 Links Copper Homeostasis to Polysaccharide Capsule Formation and Phagocytosis Inhibition in the Human Fungal Pathogen Cryptococcus neoformans
por: Chun, Cheryl D., et al.
Publicado: (2010)

Approaching the Functional Annotation of Fungal Virulence Factors Using Cross-Species Genetic Interaction Profiling
por: Brown, Jessica C. S., et al.
Publicado: (2012)

Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study
por: Manosuthi, Weerawat, et al.
Publicado: (2005)

Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial
por: Meya, David B., et al.
Publicado: (2019)

Cryptococcus neoformans Hyperfilamentous Strain Is Hypervirulent in a Murine Model of Cryptococcal Meningoencephalitis
por: Feretzaki, Marianna, et al.
Publicado: (2014)

A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi
por: Rothe, Camilla, et al.
Publicado: (2013)

Fluconazole plus flucytosine is a good alternative therapy for non‐HIV and non‐transplant‐associated cryptococcal meningitis: A retrospective cohort study
por: Li, Zhanyi, et al.
Publicado: (2019)

“Pearls”: A New Type of Open-Access Educational Resource
por: Madhani, Hiten D., et al.
Publicado: (2009)

Fluconazole (Diflucan®)
por: Hollier, Lisa M., et al.
Publicado: (1995)

Cryptococcal Cell Morphology Affects Host Cell Interactions and Pathogenicity
por: Okagaki, Laura H., et al.
Publicado: (2010)

Fluconazole Resistance and Virulence in In Vitro Induced-Fluconazole Resistant Strains and in Clinical Fluconazole Resistant Strain of Cryptococcus deuterogattii
por: Bertout, Sébastien, et al.
Publicado: (2023)

Genetic analysis of the Candida albicans biofilm transcription factor network using simple and complex haploinsufficiency
por: Glazier, Virginia E., et al.
Publicado: (2017)

A Link between Virulence and Homeostatic Responses to Hypoxia during Infection by the Human Fungal Pathogen Cryptococcus neoformans
por: Chun, Cheryl D, et al.
Publicado: (2007)

Intrinsic Toxicity of Unchecked Heterochromatin Spread Is Suppressed by Redundant Chromatin Boundary Functions in Schizosacchromyces pombe
por: Garcia, Jennifer F., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1ks5mmdtfk4paitqh5mnjqpnke